Beigene ADS Representing Action
ActionActionPrix
Questions fréquentes
Quelle est la capitalisation boursière de Beigene ADS Representing ?
Quel est le bénéfice par action (BPA) de Beigene ADS Representing ?
Quelles sont les évaluations des analystes et le prix cible de l'action Beigene ADS Representing ?
Quel est le chiffre d'affaires de Beigene ADS Representing sur les douze derniers mois ?
Quel est l'EBITDA de Beigene ADS Representing ?
Quel est le flux de trésorerie disponible de Beigene ADS Representing ?
Combien d'employés compte Beigene ADS Representing, et à quel secteur d'activité appartient-elle ?
Quel est le flottant des actions de Beigene ADS Representing ?
Finances
Capitalisation boursière
22,13 Md $USBPA (TTM)
-0,666 $USFree Float
1,31 MdRecettes (TTM)
3,27 Md $USEBITDA (TTM)
-896,43 M $USCash-flow disponible (TTM)
-1,15 Md $USCotation
Notes des analystes
L'objectif de prix est de 25,67 $US et l'action est analysée par 8 analystes.
Acheter
8
Hold
0
Vendre
0
Informations
BeiGene, Ltd. is a global biotechnology company engaged in discovering and developing oncology treatments for cancer patients worldwide. The Company has discovered and developed three approved medicines, including BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase for the treatment of various blood cancers; TEVIMBRA (tislelizumab), an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of poly ADP-ribose polymerase 1 (PARP1) and PARP2. The Company has obtained approvals to market BRUKINSA in the United States, the People's Republic of China (China or the PRC), the European Union, the United Kingdom, Canada, Australia, and additional international markets; tislelizumab in the European Union and China; and pamiparib in China. It also focuses on commercializing cancer medicines, such as XGEVA, BLINCYTO, KYPROLIS, and others in China under an exclusive license from Amgen Inc.
10 473
Biotechnology & Drugs
Soins de santé
Identifiant
ISIN
Ticker primaire